South Dakota House Bill HB1088

South Dakota 2022 Regular Session

• Introduced: 1/20/22
• Refer: 1/20/22

Caption

Limit the delta-9 tetrahydrocannabinol concentration in medical cannabis and cannabis products that may be dispensed.

Impact

The implications of HB 1088 are profound for dispensaries operating within South Dakota. By setting the THC concentration limits, the bill seeks to promote responsible consumption of cannabis among patients and to align the state's medical cannabis program with similar regulations observed in other states. Dispensaries are required to maintain detailed internal records of every transaction, specifying the quantities dispensed to both nonresident cardholders and registered patients, which adds another layer of accountability and regulation to the medical cannabis distribution chain.

Summary

House Bill 1088 aims to regulate the dispensing of medical cannabis in South Dakota by limiting the concentration of delta-9 tetrahydrocannabinol (THC) in cannabis products. Specifically, the bill restricts dispensaries from providing cannabis with more than a fifteen percent THC concentration on a dry weight basis, as well as limiting cannabis products to a similar concentration threshold. This legislation reflects a significant move towards tighter controls over medical cannabis distribution and usage, aiming to safeguard users and ensure compliance with established standards of cannabis potency.

Contention

While supporters argue that the bill will help mitigate potential misuse of cannabis due to high THC concentrations, opponents of the bill may raise concerns about access to medical cannabis for patients who may find relief in higher potency products. Critics might also argue that such regulations could complicate patient access and deter lawful dispensaries from operating effectively. The ongoing debate highlights the balancing act between ensuring patient safety and providing adequate access to those in need of effective medical treatment.